1142363-52-7|Edicotinib|4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide|-范德生物科技公司

Edicotinib

NMR下载 COA and HPLC MSDS下载
names：
4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide
CAS号：
1142363-52-7
MDL Number：
MF(分子式)： C27H35N5O2 MW(分子量)： 461.61
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Edicotinib
英文别名	JNJ40346527; JNJ 40346527; JNJ-40346527; Edicotinib;
CAS号	1142363-52-7
SMILES	O=C(C1=NC(C#N)=CN1)NC2=CC=C(C3CC(C)(C)OC(C)(C)C3)N=C2C4=CCC(C)(C)CC4
Inchi	InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
InchiKey	BNVPFDRNGHMRJS-UHFFFAOYSA-N
分子式 Formula	C27H35N5O2
分子量 Molecular Weight	461.61
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Edicotinib(CAS:1142363-52-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G,Cioce M. Inhibition of the colony-stimulating-factor-1 receptor affects theresistance of lung cancer cells to cisplatin. Oncotarget. 2016 Jul 28. doi:10.18632/oncotarget.10895. [Epub ahead of print] PubMed PMID: 27486763.

[2]Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, MantheyCL, Yan XD, Ge T, Franks C, Greenspan A. Results from a Phase IIA Parallel GroupStudy of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with ActiveRheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. JRheumatol. 2015 Oct;42(10):1752-60. doi: 10.3899/jrheum.141580. Epub 2015 Aug 1.PubMed PMID: 26233509.

[3] von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S,Aquino R, Kotoulek S, de Boer CJ, Engert A. An Open-Label, Multicenter, PhaseI/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed orRefractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. doi:10.1158/1078-0432.CCR-14-1845. Epub 2015 Jan 27. PubMed PMID: 25628399.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开